Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Enliven Therapeutics, Inc. | Director | Stock Option (right to buy) | 23.4K | Feb 13, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
ELVN | Enliven Therapeutics, Inc. | Feb 13, 2024 | 1 | $0 | 4/A | Feb 20, 2024 | Director |
ELVN | Enliven Therapeutics, Inc. | Feb 13, 2024 | 1 | $0 | 4 | Feb 15, 2024 | Director |
ELVN | Enliven Therapeutics, Inc. | Feb 23, 2023 | 1 | $0 | 4 | Apr 6, 2023 | Director |
ELVN | Enliven Therapeutics, Inc. | Feb 23, 2023 | 2 | $0 | 4 | Feb 27, 2023 | Director |
ELVN | Enliven Therapeutics, Inc. | Feb 23, 2023 | 0 | $0 | 3 | Feb 27, 2023 | Director |
ARYE | ARYA Sciences Acquisition Corp V | Jul 12, 2021 | 0 | $0 | 3 | Jul 12, 2021 | Director |